Evidence map›Paper›PMID 33906920›Full record

ArticlemBio2021

Antiviral Resistance and Phage Counter Adaptation to Antibiotic-Resistant Extraintestinal Pathogenic

Keiko C Salazar, Li Ma, Sabrina I Green, Jacob J Zulk, Barbara W Trautner, Robert F Ramig, Justin R Clark, Austen L Terwilliger, Anthony W Maresso

Registry-linked trialAbstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06559618 (A Phase 1B Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06559618 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase 1B Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

TypeinterventionalSponsorBarbara TrautnerRan2025 to 2028Enrolled30ConditionsBacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia ColiArmsPhage Therapy, Placebo
3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Phage-induced protection against lethal bacterial reinfection.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Targeted dual-receptor phage cocktail againstFrontiers in microbiology · 2024
    Article
  19. A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keiko C SalazarDepartment of Integrative Molecular and Biomedical Science, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-1845-281X
Li MaSchool of Biological and Physical Sciences, Northwestern State University, Natchitoches, Louisiana, USA.
Sabrina I GreenDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Jacob J ZulkDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Barbara W TrautnerMichael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Robert F RamigDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Justin R ClarkDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA justin.clark@bcm.edu terwilli@bcm.edu maresso@bcm.edu.
Austen L TerwilligerDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA justin.clark@bcm.edu terwilli@bcm.edu maresso@bcm.edu.
Anthony W MaressoDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA justin.clark@bcm.edu terwilli@bcm.edu maresso@bcm.edu.

Funding

Novel Platforms for Human Intestinal Enteroids: Matrix, Mechanics, and TopographyU19AI116497 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI GRANDE-ALLEN, KATHRYN JANE · 2015 to 2025
$13.2M
Organoid Cultivation CoreU19AI157981 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MARESSO, ANTHONY W · 2021 to 2025
$12.4M
Bacteriophage to treat multidrug‐resistant UTI in Persons with Spinal Cord InjuryI01RX002595 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI TRAUTNER, BARBARA WELLS · 2019 to 2023
–
NIAID NIH HHS U19 AI116497NIAID NIH HHS U19 AI157981RRD VA I01 RX002595
6 · The paper itself

Abstract

Extraintestinal pathogenic

Indexed as

Adaptation, BiologicalAnimalsAnti-Bacterial AgentsBacteriophagesBloodDrug Resistance, Multiple, BacterialEscherichia coli InfectionsExtraintestinal Pathogenic Escherichia coliFemaleGenetic FitnessHumansMiceMicrobial ViabilityPhage TherapyVirulence FactorsAnti-Bacterial AgentsVirulence Factorsantibiotic resistancebacterial evolutionbacteriophage evolutionbacteriophage resistancebacteriophage therapyhost-pathogen interactionsmultidrug resistancesepsis

Identifiers

PMID33906920
PMCPMC8092219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.